Senseonics Holdings, Inc. (SENS) News
Filter SENS News Items
SENS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SENS News From Around the Web
Below are the latest news stories about SENSEONICS HOLDINGS INC that investors may wish to consider to help them evaluate SENS as an investment opportunity.
Senseonics Holdings, Inc. (AMEX:SENS) Q3 2023 Earnings Call TranscriptSenseonics Holdings, Inc. (AMEX:SENS) Q3 2023 Earnings Call Transcript November 9, 2023 Senseonics Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.04 EPS, expectations were $-0.04. Operator: Good day and welcome to the Senseonics Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note today’s event […] |
Q3 2023 Senseonics Holdings Inc Earnings CallQ3 2023 Senseonics Holdings Inc Earnings Call |
Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial ResultsGERMANTOWN, Md., November 09, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2023. |
Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare ConferenceGERMANTOWN, Md., November 09, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY. |
Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern TimeGERMANTOWN, Md., October 30, 2023--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. |
Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with DiabetesPARSIPPANY, N.J. & GERMANTOWN, Md., October 09, 2023--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. ‘The CGM for Real Life’ campaign is designed to significantly drive awareness |
Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical StudyGERMANTOWN, Md., September 26, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient. |
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company ShowcaseGERMANTOWN, Md., September 14, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. |
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules CapitalGERMANTOWN, Md., September 11, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The company also announced it drew down $25 million upon the transaction closing. |